Purpose We conducted a systematic review of randomized trials to compare the benefits and harms of tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation.
Introduction
The therapeutic success of heart transplantation has been largely attributable to the development of effective and Electronic supplementary material The online version of this article (doi:10.1007/s00228-010-0902-6) contains supplementary material, which is available to authorized users.
balanced immunosuppressive treatment regimens [1, 2] . In particular, calcineurin inhibitors were essential in reducing acute rejection and improving early survival [2] . Two calcineurin inhibitors, cyclosporine and tacrolimus, are currently used as primary immunosuppression in heart transplant recipients [1, 2] .
Cyclosporine was discovered in 1971, and in 1983 the drug was approved for prevention or treatment of transplant rejection [3] . To overcome the intra-individual and inter-individual differences in absorption and the bioavailability of the original oil-based formulation of cyclosporine (Sandimmune®), a microemulsion formula of cyclosporine (Neoral®) was introduced in the 1990s [3] .
Tacrolimus (Prograf®) was discovered in the early 1980s and from 1989 used for the prevention of liver transplant rejection [3, 4] . Since then, its use expanded rapidly into the transplantation of other organs [3] . Both cyclosporine and tacrolimus inhibit the action of the phosphatase calcineurin. Calcineurin regulates the transport of NFAT (nuclear factor of activated T-cells), which is a transcription factor regulating lymphokine gene transcription. Cyclosporine and tacrolimus exert their cellular effects on the action of calcineurin through different cytoplasmatic receptors, as cyclosporine binds to cyclophilins and tacrolimus binds to FK-binding proteins [5] . Differences between cyclosporine and tacrolimus with regard to adverse effects, safety, and tolerability have been observed, but the toxicodynamic molecular mechanism of both drugs is still largely unknown and the involvement of calcineurin inhibition in calcineurin inhibitor toxicity is unclear [6] .
To date, several randomized trials have compared tacrolimus and cyclosporine, but results have been inconsistent and the optimal immunosuppressive maintenance therapy continues to be debated [5, 6] . We conducted this systematic review to compare benefits and harms of tacrolimus vs cyclosporine in heart transplant recipients.
Materials and methods

Trial selection and characteristics
Our review followed the Cochrane Collaboration [7] and PRISMA guidelines [8] . A protocol was developed (www. ctu.dk/protocols) and we included all randomized trials comparing tacrolimus and cyclosporine after first-time isolated heart transplantation. We required that all the patients included received the same additional immunosuppressive therapy within each trial. Our preselected outcome measures were mortality, acute severe rejection defined as cardiac biopsies of grade 3A or higher according to the classification of the ISHLT (equivalent to grade H2R in the recently revised classification) [9] ; acute rejection causing haemodynamic instability; Cytomegalovirus (CMV) infection; basocellular skin cancer; all malignancies excluding basocellular skin cancer; arterial hypertension; diabetes mellitus; hyperlipidaemia; total serum cholesterol; renal failure requiring haemodialysis; serum creatinine levels; neurotoxicity; hirsutism; and gingival hyperplasia. Our preselected subgroup analyses included:
1. Low-risk bias compared with high-risk bias trials 2. Microemulsion cyclosporine compared with oil-based cyclosporine formulation 3. Total population (adult and paediatric studies) compared with adult studies only (www.ctu.dk/protocols)
Search strategy
We searched The Cochrane Central Register of Controlled Clinical Trials (CENTRAL), MEDLINE, EMBASE, and the Science Citation Index Expanded (up to April 2010) [10] . Search terms were (c*closporin* or CyA or Neoral* or Sandimmun*) combined with (tacrolimus or FK506 or FK 506 or Prograf) and "heart transplantation" (MESH term) and (random* or blind* or placebo* or meta-analysis). We scanned bibliographies of relevant articles for additional trials. We had no restrictions with regard to blinding, language, or publication status.
Data extraction and quality assessment
Three authors independently assessed trial eligibility (LP, CHM and FG). We assessed the impact of bias risk by evaluating the trials with respect to generation of the allocation sequence, allocation concealment, blinding and reporting of incomplete outcome data [11] . Generation of the allocation sequence was considered adequate when generated by a computer, random-number table, shuffling of cards, or similar. Allocation concealment was considered adequate when allocation of patients involved a central independent unit, such as an on-site locked computer, sealed envelopes or similar. Blinding was adequate if the trial was described as double-blind and the method of blinding involved identical active drugs. Post-randomization exclusion of patients was registered. When possible we converted per-protocol to intention-to-treat-analysis. Bias risk was assessed without blinding by three authors [11] .
Quantitative data synthesis
We used Cochrane Collaboration Software (RevMan 5.0.22). Data were analysed with both fixed-effect and random-effects models. In the case of a discrepancy with regard to the significance between the two models both results were reported. Otherwise, only results from the random-effects model were reported. Data were presented as relative risk (RR) with values less than 1.0 favouring tacrolimus, and with 95% confidence intervals (CI). Heterogeneity was assessed with I 2 , which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). I 2 lies between 0% (no heterogeneity) and 100% (maximal heterogeneity) [12] . Test of interaction was performed to evaluate the difference between the two estimates [13] .
Trial sequential analysis
Trial sequential analysis was applied as cumulative metaanalyses are at risk of producing random errors because of sparse data or repetitive testing on accumulating data [14] . To minimise random errors we calculated the required information size (i.e. the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) [14] . Information size calculation also accounted for the diversity present in the meta-analysis. In our metaanalysis, information size was based on the assumption of a plausible RR reduction of 20% [14] . The underlying assumption of trial sequential analysis is that significance testing may be performed each time a new trial is added to the meta-analysis. We added the trials according to the year of publication. On the basis of the required information size and risk for type I and type II errors trial sequential monitoring boundaries were constructed [14] . These boundaries will determine the statistical inference one may draw regarding the cumulative meta-analysis that has not reached the required information size. If a trial sequential monitoring boundary is crossed before the required information size is reached in a cumulative metaanalysis, firm evidence may have been established and further trials are superfluous. On the other hand, if the boundaries are not surpassed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. We used as defaults a type I error of 5%, a type II error of 20%, and adjusted the information size for diversity unless otherwise stated [14] . Figure 1 depicts the results of the search strategy. Database searches identified 463 references. Exclusion of duplicates and irrelevant references left 11 randomised trials published in 25 publications . One trial could not be included in the meta-analysis as none of the outcome measures were addressed [29] . We confirmed with the authors that all patients only participated once in the trials [28, 30] The meta-analyses involved 10 trials with a total of 952 patients (Table 1) : 486 patients were randomized to tacrolimus and 466 patients to cyclosporine [15, 16, 19, 20, [24] [25] [26] [27] [28] 30] ). Three trials with 192 patients compared tacrolimus with the old formula oil-based cyclosporine [24, 26, 27] and seven trials with 760 patients compared tacrolimus with the new formula microemulsion cyclosporine [15, 16, 19, 20, 25, 28, 30] .
Results
In 8 trials the population consisted of adult patients [15, 19, 20, 24, [26] [27] [28] 30] , while in 1 trial the population consisted of a combination of adult and paediatric patients [16] , and in 1 trial only paediatric patients were included [25] .
Concomitant immunosuppressive treatment was the same within all trials except for 1 where the patients were randomised to 3 groups: 1 receiving cyclosporine and mycophenolate mofetil, 1 receiving tacrolimus and mycophenolate mofetil, and 1 receiving tacrolimus and sirolimus [19] . We therefore excluded the latter group from our analyses. Immunosuppressive treatment varied within trials. All patients were treated with steroids. As an antiproliferative agent azathioprine (7 trials [15, 16, [24] [25] [26] [27] [28] ) or mycophenolate mofetil (3 trials [19, 20, 30] ) was used. Induction therapy was used for all patients in 4 trials [15, 25, 26, 28] , for some of the patients in 3 trials [19, 24, 27] , and for none in 3 trials [16, 20, 30] . If induction therapy was used, either anti-thymocyte globulin (ATG) or muromonab-CD3 (OKT3®) was administered [15, 25, 26, 28] . Patients were followed from 6 months to 5 years.
Trial methodology was inadequately reported in the majority of trials ( Table 2 ). All trials were considered trials with a high risk of bias. The significant difference in mortality between tacrolimus and microemulsion cyclosporine, however, disappeared when the studies including paediatric patients were excluded (RR 0.66; 95% CI 0.40-1.09, p=0.10). The test of interaction showed no significant differences in mortality between the paediatric and adult cyclosporine subgroups (p=0.89). This suggests that the lack of significance caused by withdrawing paediatric studies was solely caused by reducing the number of patients in the groups.
Acute rejection
No significant difference in grade 3A or higher rejection was found between tacrolimus and (both formulacombined) cyclosporine (RR 0.86; 95% CI 0.62-1.20, p=0.38; Fig. 3 ). However, tacrolimus was associated with a significant reduction in Grade 3 A or higher rejection compared with microemulsion cyclosporine (RR 0.71; 95% CI 0.56-0.90, p=0.004).
Rejection causing haemodynamic instability was reported in 5 trials comparing tacrolimus with microemulsion cyclosporine and no significant difference was found (RR 0.96; 95% CI 0.34-1.38, p=0.29). 
Malignancies
According to our protocol we analysed malignancies as basocellular skin cancer and all other cancers excluding basocellular skin cancer. Three trials found no significant difference between tacrolimus and microemulsion cyclosporine for basocellular skin cancer (RR 1.20; 95% CI 0.29-4.93, p= 0.80). Four trials reported on other cancers and found no significant difference between tacrolimus and cyclosporine (RR 0.57; 95% CI 0.20-1.63, p=0.85). Nor did we find any significant difference when subgroup analysis for the microemulsion and oil-based cyclosporine was applied.
Hypertension
Eight trials found significantly less hypertension in patients treated with tacrolimus compared with cyclosporine (RR 0.80; 95% CI 0.69-0.93, p=0.003; Fig. 4 ). In addition, subgroup analysis showed that hypertension was less common for tacrolimus compared with oil-based cyclosporine (RR 0.66; 95% CI 0.54-0.80, p<0.0001). An insignificant trend was seen towards less hypertension for tacrolimus compared with microemulsion cyclosporine (RR 0.88; 95% CI 0.77-1.01, p=0.07). The difference was significant when a fixed-effect model was applied (RR 0.86; 95% CI 0.78-0.95, p=0.003).
Hyperlipidaemia
Four trials reported on the number of patients treated pharmacologically for hyperlipidaemia and 5 trials reported on total serum cholesterol. Significantly fewer patients treated with tacrolimus received treatment for hyperlipidaemia compared with cyclosporine (RR 0.57; 95% CI 0.44-0.74, p< 0.0001; Fig. 5 ). This was seen both for patients treated with oil-based cyclosporine (RR 0.57; 95% CI 0.38-0.87, p= 0.009) and those treated with microemulsion cyclosporine (RR 0.57 95% CI 0.41-0.79, p=0.0009).
In addition, we found that tacrolimus significantly lowers total cholesterol compared with cyclosporine (mean difference 0.4 mmol/L; 95% CI −0.66 to −0.22 mmol/L, p<0.0001). This was seen for both the oil-based (p= 0.005) and for the microemulsion (p=0.002) subgroups, and the effect was seen even though in some of the trials more patients in the cyclosporine group were on cholesterol-lowering therapy.
Diabetes
Eight trials reported on diabetes. An insignificant trend towards more diabetes was seen in tacrolimus compared with cyclosporine (RR 1.35; 95% CI 0.93-1.94, p=0.11; Fig. 6 ). No significant difference was seen for subgroup analyses of oil-based cyclosporine (RR 1.07, 95% CI 0.40-2.90, p=0.89) and microemulsion cyclosporine (RR 1.50, 95% CI 0.90-2.50, p=0.12). When the fixed-effect model was applied, we found significant differences between tacrolimus and cyclosporine (RR 1.24; 95% CI 1.02-1.49, p=0.03) and tacrolimus and microemulsion cyclosporine (RR 1.25 95% CI 1.03-1.51, p=0.02).
Renal function
No significant difference between tacrolimus and cyclosporine was seen concerning renal failure requiring haemodialysis (RR 1.45; 95% CI 0.50-4.26, p=0.49). In addition, no significant difference was seen for subgroup analyses of oil-based cyclosporine and microemulsion cyclosporine. Serum creatinine at end of the trials (n=6) was 8 μmol/L lower in patients treated with tacrolimus compared with cyclosporine; however, this difference was not significant (95% CI −18.3 to −1.7 μmol/L, p=0.11). Nor was any significant difference seen in serum creatinine with regard to subgroup analyses of oil-based cyclosporine and microemulsion cyclosporine.
Chronic allograft vasculopathy
Five trials reported on chronic allograft vasculopathy, and no significant difference was found for tacrolimus compared with cyclosporine (RR 1.22; 95% CI 0.72-2.05, p= 0.46). Nor was any difference found with regard to subgroup analysis on oil-based cyclosporine and microemulsion cyclosporine.
Hirsutism and gingival hyperplasia
Hirsutism was reported in 2 trials and was significantly less frequently seen in patients treated with tacrolimus than in those treated with microemulsion cyclosporine (RR 0.17; 95% CI 0.04-0.62, p = 0.008). Gingival hyperplasia was reported in 3 trials and was significantly 
Neurotoxicity
Neurotoxicity was reported in 5 trials and was analysed as the number of patients who experienced at least one neurotoxic reaction or stroke. No significant difference was observed (RR 1.31; 95% CI 0.58-3.00, p=0.50). Nor was any significant difference detected when subgroup analysis of the microemulsion and oil-based cyclosporine was applied.
Adult patients
We performed subgroup analysis for only adult patients by excluding the 2 trials with any paediatric participants [16, 25] . We did not find any differences with regard to any of the outcome measures except for the difference in mortality, which was described above.
Trial sequential analysis
Trial sequential analysis was performed for the statistically significant difference in mortality seen for tacrolimus and the microemulsion cyclosporine group. In this analysis was the required information size not obtained and were the sequential monitoring boundaries not broken by the cumulative Z-curve.
Discussion
Principal findings
Our systematic review has generated a number of important findings. Tacrolimus seems to be significantly superior to both types of cyclosporine with regard to hypertension, hyperlipidaemia, hirsutism and gingival hyperplasia. Furthermore, tacrolimus seems to be significantly superior to microemulsion cyclosporine with regard to mortality and acute, severe, biopsy-proven rejection.
Strengths
Our systematic review of randomised trials offers a number of advantages. We conducted our review according to a protocol following the recommendations of the Cochrane Collaboration [7] and published our protocol before conduction of the review (www.ctu.dk/protocols). We systematically searched a number of databases and reference lists for randomised trials, which should have reduced the selection bias to a minimum [40] . We selected trials and extracted data in triplicate. We conducted sensitivity analyses using different models. We considered the risk of systematic errors ("bias"), the risks of random errors ("play of chance"), as well as the risk of design errors (e.g. the type of cyclosporine) [40] . We reported our findings in accordance with PRISMA [8] .
Limitations
This systematic review also encompasses some limitations. The quality and quantity of available evidence limited our findings and interpretations. All trials had a high risk of bias [40] . Moreover, only a few patients with relatively few outcomes were included in the trials. Hence, the risks of random errors were potential explanations of our findings as suggested by our trial sequential analyses on mortality. In addition, patients included in randomised trials may not be representative of the general patient population. For instance, most trials included in the current review did not include patients who were bridged to transplantation with a left ventricular device. The proportion of patients bridged to transplantation with an assist device has been increasing in the general heart transplantation population and consisted of 19% in a recent analysis [1] . Moreover, in recent years heart transplant recipients have become older during technical evolution, with currently 25% of all heart transplants performed in people over 60 years of age [1] . These factors could potentially influence the external validity of the included trials.
Perspective
In our meta-analysis tacrolimus was found to be superior to the new microemulsion cyclosporine with regard to mortality in terms of risk of dying, but no significant difference between tacrolimus and the old formula oilbased cyclosporine was observed. The question arises as to how this difference can be explained, as microemulsion cyclosporine was introduced to overcome the differences in absorption and the oral bioavailability of the original oilbased formulation of cyclosporine [2] . Microemulsion cyclosporine results in higher maximum cyclosporine concentrations than oil-based cyclosporine, even when cyclosporine trough (C0) levels are similar, which might influence tolerability and toxicity. A randomised multicentre trial comparing both cyclosporine formulas found more consistent bioavailability of the microemulsion formula, resulting in less severe acute rejection in patients treated with the new formula; however, no significant difference in mortality was found at 24 months' follow-up in 380 patients [41] .
Concerning the difference in mortality observed for the two different cyclosporine formulas in our metaanalysis, it should be noted that clinical experience with tacrolimus was more limited in the trials comparing this drug with oil-based cyclosporine than in the trials comparing tacrolimus with microemulsion cyclosporine, and tacrolimus blood target levels were higher in the trials with oil-based cyclosporine than in the trials with microemulsion cyclosporine [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 30] . However, a randomised trial comparing low and high tacrolimus doses in heart transplant recipients did not find any significant difference in mortality, but a more favourable safety profile for the patients treated with a low tacrolimus dose resulted [42] .
Traditionally, cyclosporine dosing has been based on trough cyclosporine level (C0) monitoring [43] . Cyclosporine level at 2 h post-dose (C2) has, however, been found to be the best single time-point predictor of a 0-to 4-h abbreviated area under the absorption curve (AUC 0-4 ) in heart, lung, kidney and liver transplant recipients [43, 44] . Clinical benefits have been shown for other solid organ recipients when C2 monitoring was applied compared with C0 [44] . For heart transplant recipients the picture is more unclear as one large trial did not find a correlation between C2 levels and the incidence of rejection [44] . It appears though, that in general, a lower C2 level may be sufficient to prevent rejection, and with lower levels different adverse effects might be expected [43, 44] . None of the trials in this meta-analysis applied C2 levels for therapeutic drug monitoring of cyclosporine, and we were therefore not able to analyse C0 compared with C2 monitoring in our trial.
The statistical significant difference in mortality between tacrolimus and microemulsion cyclosporine disappeared when two trials including paediatric patients were excluded. However, results for the different trials were consistent and none of the trials found tacrolimus to be inferior to microemulsion cyclosporine. No significant difference between adult and paediatric patients was found when the test of interaction was performed. This suggests that the lack of significance caused by withdrawing paediatric studies was caused by reducing the number of patients in the groups.
Our meta-analysis found tacrolimus to be associated with less severe acute biopsy-proven rejection compared with microemulsion cyclosporine. This is in line with observational data from the ISHLT showing that 19% of patients who at transplant discharge were receiving tacrolimus and mycophenolate mofetil suffered a treated rejection compared with 27% of patients receiving cyclosporine and mycophenolate mofetil (p<0.0001) [1] .
The results of another meta-analysis regarding tacrolimus versus microemulsion cyclosporine are slightly different from those of our systematic review [45] . This might be explained by the following: we found additional randomised trials comparing tacrolimus with microemulsion cyclosporine [30] , we excluded studies that were not properly randomised [46] , and we excluded study groups where there were differences in concomitant immunosuppressive medication between the tacrolimus and cyclosporine treatment groups [19] . Furthermore, we included trials comparing tacrolimus with oil-based cyclosporine [24, 26, 27] .
Traditionally, immunosuppressive treatment for heart transplantation has gained much experience from knowledge regarding other types of organ transplantation. A meta-analysis comparing tacrolimus versus cyclosporine in 3,813 liver transplant recipients found tacrolimus to be superior to cyclosporine in improving patient and graft survival and preventing acute rejection after liver transplantation; however, tacrolimus was significantly more diabetogenic than cyclosporine [47] . A meta-analysis comparing tacrolimus versus cyclosporine in 4,102 kidney transplant recipients found tacrolimus to be superior to cyclosporine in improving graft survival and preventing acute rejection after kidney transplantation; however, tacrolimus was found to increase post-transplant diabetes, neurological, and gastrointestinal adverse effects [48] . The reduction in acute rejection and mortality seen in kidney and liver transplant recipients treated with tacrolimus was only seen in our subgroup of heart transplant recipients where tacrolimus was compared with microemulsion cyclosporine. In contrast to kidney and liver transplant recipients, we did not find a significant difference in diabetes in heart transplant recipients; however, an insignificant trend towards more patients with diabetes in the tacrolimus group was seen.
Conclusion
Recognising the limitations of the study due to the size and nature of the trials included, our systematic review shows that tacrolimus seems superior to cyclosporine in heart transplant recipients with regard to hypertension, hyperlipidaemia, hirsutism and gingival hyperplasia. In addition, tacrolimus seems to be superior to microemulsion cyclosporine with regard to mortality and acute, severe, biopsy-proven rejection. Given the result of our analysis it appears that an appropriately sized, randomised trial of tacrolimus versus microemulsion cyclosporine using contemporary target levels and adjunctive immunosuppression in cardiac transplantation is warranted to determine whether the results of the present meta-analysis can be confirmed.
